Novo Nordisk Battles Price War on Two Fronts: Implant Innovation and Medicare Access vs. Margin Erosion
Published on 07/08/2026 at 11:55 | Redaktion boerse-global.de
Novo Nordisk finds itself navigating a sharply divided landscape. On one side, a promising pipeline of next-generation treatments and surging prescription volumes. On the other, a relentless pricing squeeze that has already prompted a prominent fund manager to label the stock an "investment disaster."
The Danish pharmaceutical giant has struck a partnership with Vivani Medical to develop NPM-139, a semaglutide implant designed to deliver a steady dose once or twice a year. A Phase 1 clinical trial is slated to begin in mid-2026, comparing the implant directly with injectable Wegovy. Separately, an oral Wegovy tablet reached one million prescriptions within twelve weeks of its US launch on 5 January 2026, and had crossed three million after just over five months. More than 80% of new prescriptions come from patients who had never used a GLP-1 therapy before, suggesting market expansion rather than mere share gains.
Yet the enthusiasm over innovation is tempered by hard realities in pricing. Since 1 July 2026, a Medicare bridge program has capped the out-of-pocket cost for GLP-1 medicines like Wegovy at $50 per month for eligible seniors, while the government’s purchase price is fixed at $245. From January 2027, Novo Nordisk will cut the US list price for all doses of Wegovy, Ozempic and Rybelsus to $675 per month — roughly a 50% reduction for Wegovy and a 35% cut for Ozempic. CEO Maziar Mike Doustdar warned in February of a profit decline of up to 13% this year, attributing the drop to the planned rebates.
The pricing pressure has spooked investors. Terry Smith, founder of Fundsmith, sold his entire stake in Novo Nordisk during the first half of 2026, describing the company’s handling of its once-dominant market position as an "investment disaster." The exit formed part of a broader portfolio cleanup. Around the same time, analysts downgraded the stock to "hold" in early July.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The share price response has been mixed. After closing at €43.43 on Tuesday, Novo Nordisk shares recently traded at €42.58, a decline of nearly 2% on the day. Year to date, the stock is down 4.70%, and it has fallen 28.52% over the past twelve months. The current level stands 30.42% below the 52-week high of €61.20 reached in July 2025, but 40.76% above the 52-week low of €30.25 from March.
Technical indicators point to conflicting signals. The 14-day relative strength index sits at 62, while a broader RSI reading of 68.9 suggests the stock has entered overbought territory. The shares are trading above both the 50-day moving average of €39.20 and the 100-day average of €36.43, reflecting a 19.29% gain over the past 30 days. That short-term strength, however, does little to offset the longer-term slide.
Investors are now waiting for the next fundamental test. Novo Nordisk is scheduled to report second-quarter earnings on 5 August 2026, when management will face questions about margin erosion and the performance of the oral Wegovy tablet, which captured 65% of new US prescriptions in the previous quarter. The question hanging over the stock is whether surging demand — including a distribution deal with Amazon for same-day delivery of oral versions and the Medicare initiative — can compensate for the margin damage inflicted by price cuts.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The Vivani partnership adds a further long-term variable. The implant, if successful, could offer patients a convenient alternative to injections. But for now, the market remains fixated on the near-term trade-off between volume and profitability, a balance that will determine whether Terry Smith’s verdict proves premature or prescient.
Ad
Novo Nordisk Stock: New Analysis - 8 July
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
